Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

The challenge of approving add-on therapies for patients with metastatic cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 05.07.17
Views: 3848

Dr David Montgomery, Alexander Smith

Dr David Montgomery (Medical Director, Pfizer, UK) and Alexander Smith (Pfizer, UK) speak about the complexities of health economics and how they affect access to medicine in the UK, particularly for add-on treatments.

The video explores the different equations used by NICE to evaluate cost effectiveness for drugs for combination therapies compared to a simple side-by-side judgement of monotherapies.

The video sets out to explain the QALY measurement (Quality Adjusted Life Year) and the Incremental Cost Effectiveness Ratio (ICER) with examples worked through the NICE process. 

Dr Montgomery sets out to demonstrate the problems in the current system used by NICE which means that new therapies are not being authorised for use by the NHS.

Dr Montgomery calls for a debate on how immuno-oncology and personalised medicine treatments are assessed going forward.

This film has been developed and funded by Pfizer Ltd.

Read more about how to shape personalised medicine policy here.

Related videos

follow us

Tobacco Dependence e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation